** Brokerage Mizuho raises healthcare conglomerate CVS Health's CVS.N PT to $70 from $58, with "outperform" rating
** New PT represents ~14% upside to the stock's close
** Brokerage says CVS is "an attractive investment opportunity given the diversification of its business"
** "We believe CVS' long-term adjusted EPS growth floor is predicated on market share gains and the success of the company's new cost-plus pharmacy reimbursement model" - brokerage adds
** Eighteen of 29 brokerages rate the stock "buy" or higher, eleven "hold"; their median PT is $70.89 - data compiled by LSEG
** CVS has fallen 12.4% in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。